Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06188741 · ClinicalTrials.gov registry record · Phase 2
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
A Phase 2 study of Neurofibromatosis 1 and Plexiform Neurofibroma, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 13
- Study locations
NCT06188741 is a Phase 2 study of Neurofibromatosis 1 and Plexiform Neurofibroma that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 200 participants, below the 1,027-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (81% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT06188741, a Phase 2 study of Neurofibromatosis 1 and Plexiform Neurofibroma, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 13
- Study locations
Study Summary
Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in clinically meaningful benefit such as improvement in pain or range of motion. However, many morbidities, such as blindness or nerve damage, cannot be fully reversed with PN shrinkage. Therefore, there remains a critical need in this patient population to determine if young participants with PN in high-risk locations may benefit from early medical intervention prior to the development of clinical problems. This study will determine whether participants with asymptomatic PN in high-risk locations can potentially benefit from early treatment with selumetinib.
Conditions Studied
Interventions
- DRUG Selumetinib
Study Locations (13)
Illinois
- Lurie Children's Hospital of Chicago - Chicago
- University of Chicago - Chicago
Maryland
- Johns Hopkins University - Baltimore
- National Cancer Institute/ National Institutes of Health - Bethesda
Alabama
- Childrens of Alabama - Birmingham
California
- Children's Hospital of Los Angeles - Los Angeles
District of Columbia
- Children's National Hospital - Washington D.C.
Indiana
- Riley Hospital for Children/Indiana University - Indianapolis
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-08-27 |
| Est. Completion | 2032-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06188741
The ClinicalTrials.gov registry entry for NCT06188741 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,027-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (81% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 1 intervention - of which Selumetinib is the first listed.
NCT06188741 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Illinois, Maryland, Alabama.
Frequently Asked Questions
What is clinical trial NCT06188741 about?
NCT06188741 is a clinical study titled "Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1". Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in cl...
What is the current status of trial NCT06188741?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-08-27. Estimated completion is 2032-09-01.
What conditions does trial NCT06188741 study?
This clinical trial studies the following conditions: Neurofibromatosis 1, Plexiform Neurofibroma.
What interventions are being tested in trial NCT06188741?
The interventions under investigation include: Selumetinib (DRUG).
Who is sponsoring clinical trial NCT06188741?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06188741 being conducted?
This trial has 13 study locations across Alabama, California, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
RECRUITING · Phase 2
-
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
ACTIVE NOT RECRUITING · Phase 2
-
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
COMPLETED · Phase 2
-
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
RECRUITING · NA
-
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
RECRUITING · NA
-
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.